This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

This educational series guides clinicians through the full continuum of inflammatory bowel disease (IBD) care, from diagnosis to long-term management. Learners begin by distinguishing IBD from other gastrointestinal disorders and assessing disease severity, then explore the underlying immunopathogenesis to understand therapeutic targets. The program emphasizes individualized treatment decisions, practical case reviews, and a treat-to-target approach that advances patients toward sustained remission. Learn to evaluate treatment success and make informed choices about switching or maintaining therapy to achieve optimal outcomes.

This program explores evolving strategies for low-density lipoprotein cholesterol (LDL-C) management in patients at high cardiovascular (CV) risk who have not yet experienced a myocardial infarction or stroke. Drs. Bohula and Leiter discuss unmet needs, shifting LDL-C targets, and emerging treatment strategies, including PCSK9 inhibitors and results from the VESALIUS-CV trial. The conversation highlights how early, intensive LDL reduction can meaningfully lower the risk of first CV events. Practical guidance is shared on risk assessment, statin optimization, evaluating and managing statin intolerance, and the use of combination lipid-lowering therapy.

In this on-demand webcast, leading experts in brain health provide guidance for patient education, discussion, and management geared toward HCPs in primary care who are at the forefront of an aging population at risk of cognitive decline trying to plan for its future and for whom brain health is a topic of uttermost importance.

This podcast reviews the International Psoriasis Council (IPC) 2025 guidance on reclassifying psoriasis severity and redefining failure of topical therapies. Clinical features such as high-impact disease sites, failure of topical treatment, or BSA >10% all factor into whether patients are candidates for systemic therapy in this new guidance. Despite broad endorsement, many clinicians remain uncertain about applying the new framework. This activity aims to raise awareness, clarify updated criteria, and align practice with current evidence supporting earlier use of IL-23 and IL-17 inhibitors in appropriate patients.

The Duchenne muscular dystrophy (DMD) treatment landscape continues to evolve, with promising therapies emerging from new insights into disease biology. This activity explores the role of aberrant histone deacetylase (HDAC) activity in DMD pathophysiology, including its impact on inflammation, muscle degeneration, adipogenesis, and fibrosis. You’ll review the latest clinical trial data and real-world evidence for novel therapies and understand where they may fit within complex, existing treatment regimens. Through practical case scenarios, the program highlights how to integrate new approaches into polypharmacy strategies. Stay ahead of the science and get ready to apply it.

In this expert commentary, Dr. Narayanaswami highlights key messages from the Prova Education satellite symposium held at the 2025 AANEM Meeting in San Francisco. The discussion centers on the clinical application of FcRn antagonists in gMG, reviewing the rationale for FcRn blockade, approved FcRN antagonists, and pivotal clinical trial data. Differences in therapy onset, duration, administration, and tolerability are outlined, along with considerations for treatment selection based on antibody profiles and diagnostic criteria. Practical insights address use in special populations, coordination with plasma exchange, and vaccination timing, offering clinicians a concise synthesis of the symposium’s clinical guidance.

This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.

This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.

This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.

This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.

This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.

This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.

This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.

This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.

This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.

This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.

On-demand webcast of expert faculty presentation on the disease burden of pediatric atopic dermatitis and strategies for helping patients achieve disease control with systemic therapy.

This CME activity focuses on enhancing clinician recognition and management of autosomal dominant hypocalcemia type 1 (ADH1). Learners will explore the pathophysiology and clinical manifestations of ADH1, understand barriers to timely diagnosis, gain practical strategies for implementing and interpreting genetic testing, and evaluate emerging therapies—such as calcilytics—that target CaSR mutations. By improving diagnostic accuracy, enabling timely and evidence-based interventions, and improving knowledge of emerging treatments, this activity aims to advance clinical outcomes for patients with ADH1.

This three-part educational activity reviews the burden of respiratory syncytial virus (RSV) and evidence-based strategies to prevent disease in infants and young children. Chapter 1 examines the epidemiology of RSV and outlines current prophylactic options, including maternal vaccination and the monoclonal antibodies nirsevimab (approved 2023) and clesrovimab (approved 2025). Chapter 2 summarizes American Academy of Pediatrics (AAP) recommendations with guidance on timing, maternal vaccination status, coadministration, and the importance of hospital-based immunization for newborns. Chapter 3 focuses on effective parent–clinician communication, emphasizing shared decision-making, addressing concerns and misinformation, and supporting timely immunization to reduce RSV-related morbidity and mortality.

Expert faculty Drs. Luca Busetto and Kirsi H. Pietiläinen discuss the importance of early intervention in obesity management to prevent progression and obesity related complications. They examine the evolving therapeutic landscape, including GLP-1 and GIP-based medications like semaglutide and tirzepatide. The conversation highlights real-world evidence and addresses the shift from weight-centric to holistic clinical approaches, as seen in updated European and Canadian guidelines. Monitoring strategies—including satiety, nutritional status, physical activity, and side effects—are explored as key elements in long-term obesity care. The dialogue underscores the chronic nature of obesity and the importance of patient-centered care.

In this Chairperson’s Perspective, Dr. Jose Rubio and Dr. Jonathan Meyer explore the evolving landscape of schizophrenia treatment through muscarinic receptor modulation. They compare the mechanisms of action, efficacy, and side effect profiles of muscarinic antipsychotics, such as xanomeline-trospium, with traditional dopamine D2 antagonists. The discussion addresses key clinical considerations for transitioning between dopaminergic and muscarinic therapies, including cholinergic burden and cross-titration timing. This expert dialogue provides relevant guidance for clinicians aiming to incorporate muscarinic therapies into personalized treatment plans for schizophrenia.

Dr. Jürgen Floege, co-chair of the KDIGO Work Group, and Dr. Jörg Latus review the updated KDIGO 2025 guidelines for managing immunoglobulin A nephropathy (IgAN) and IgA vasculitis (IgAV), which emphasize diagnostic criteria, proteinuria-based treatment thresholds, and revised therapeutic goals. The discussion focuses on the new KDIGO proteinuria treatment goal of <0.3 g/d and the use of combination therapy targeting immune modulation and CKD management. In addition, they highlight the use of Nefecon, a disease-modifying therapy now recommended as a first-line treatment where approved.

Enhance your ability to apply shared decision-making in patients with HF and LVEF ≥40%. Through real-world clinical vignettes, Dr. Scott Solomon illustrates how to uncover patient goals, clearly communicate risks and benefits, and build collaborative treatment plans. The session emphasizes early use of SGLT2 inhibitors and finerenone to reduce hospitalizations, improve quality of life, and optimize long-term outcomes.

For patients with heart failure with reduced ejection fraction (HFrEF), optimizing therapy is an important part of treatment and care. But not all patients may be reaching their treatment goals and can continue to face substantial residual risk despite the use of quadruple pharmacologic guideline-directed medical therapy (GDMT) and medical devices. A soluble guanylate cyclase (sGC) stimulator that targets a previously unaddressed pathway in HFrEF and complements other GDMT may provide an incremental benefit to patients to positively impact outcomes.

Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents directly to cancer cells while sparing healthy tissue. Two such agents, raludotatug deruxtecan and CUSP06, are currently under active investigation. In this activity, Drs. Joyce Liu and Kathleen Moore review the rationale for CDH6-directed ADCs in platinum-resistant ovarian cancer, the supporting clinical data from these agents, and the relevance of these findings to clinical practice.

Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents directly to cancer cells while sparing healthy tissue. Two such agents, raludotatug deruxtecan and CUSP06, are currently under active investigation. In this activity, Drs. Joyce Liu and Kathleen Moore review the rationale for CDH6-directed ADCs in platinum-resistant ovarian cancer, the supporting clinical data from these agents, and the relevance of these findings to clinical practice.

Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents directly to cancer cells while sparing healthy tissue. Two such agents, raludotatug deruxtecan and CUSP06, are currently under active investigation. In this activity, Drs. Joyce Liu and Kathleen Moore review the rationale for CDH6-directed ADCs in platinum-resistant ovarian cancer, the supporting clinical data from these agents, and the relevance of these findings to clinical practice.

Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents directly to cancer cells while sparing healthy tissue. Two such agents, raludotatug deruxtecan and CUSP06, are currently under active investigation. In this activity, Drs. Joyce Liu and Kathleen Moore review the rationale for CDH6-directed ADCs in platinum-resistant ovarian cancer, the supporting clinical data from these agents, and the relevance of these findings to clinical practice.

Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents directly to cancer cells while sparing healthy tissue. Two such agents, raludotatug deruxtecan and CUSP06, are currently under active investigation. In this activity, Drs. Joyce Liu and Kathleen Moore review the rationale for CDH6-directed ADCs in platinum-resistant ovarian cancer, the supporting clinical data from these agents, and the relevance of these findings to clinical practice.

Metabolic dysfunction-associated steatohepatitis (MASH) with compensated cirrhosis is associated with poor prognosis due to a high risk of hepatic decompensation, hepatocellular carcinoma, cardiovascular events, and death. Using noninvasive diagnostic tools like FIB-4, VCTE, and Agile 4, clinicians can accurately identify cirrhosis and clinically significant portal hypertension without the need for biopsy. Management focuses on preventing hepatic decompensation through beta-blocker therapy (particularly carvedilol), nutritional optimization, and hepatocellular carcinoma surveillance. Novel therapies such as efruxifermin and resmetirom may reverse fibrosis. This evidence-driven approach aims to improve outcomes in patients with MASH-related compensated cirrhosis.

This activity will cultivate familiarity with the emerging CELMoD treatment class poised to transform the management of newly-diagnosed and R/R MM. With a higher affinity for cereblon than their predecessors, CELMoDs represent a new, distinct generation of immunomodulatory drugs with the potential to bridge longstanding treatment gaps for patients exhibiting inadequate responses to the conventional medications. This activity will help providers differentiate CELMoDs from newer, alternative agents used in MM, examine the latest clinical trial data supporting the adoption of these drugs, and readily identify the clinical circumstances in which their use would be warranted in clinical practice. By participating, clinicians can additionally examine the utility of emerging combination strategies that maximize the therapeutic synergies of CELMoDs with other newer treatment classes, such as EZH2 inhibitors. In doing so, community hematologist-oncologists can substantially extend patient survival and improve the patient experience through each phase of the MM care continuum.

Approximately 75% to 90% of patients with depression experience insomnia. This means that a very significant portion of individuals struggling with depression also have difficulty sleeping. Join Drs. Michael Thase and Andrew Krystal for this expert discussion to learn about the most recent data presented at the Psych Congress 2025 in San Diego on emerging therapies, such as the selective OX2R antagonists to treat major depressive disorder with insomnia.

Corticosteroids remain a cornerstone in Duchenne muscular dystrophy (DMD) management, but evolving therapies demand a more nuanced approach. This case-based activity explores how to proactively monitor and manage corticosteroid-associated side effects through interdisciplinary care coordination. Strengthen your care strategy as the DMD treatment landscape continues to shift.

Chronic kidney disease (CKD) is a common complication in type 2 diabetes that is closely linked to cardiovascular risk and often diagnosed late. Early detection with UACR and eGFR, plus treatment with therapies such as SGLT2 inhibitors, finerenone, and GLP-1 receptor agonists, has transformed treatment and guideline recommendations. Attention is now shifting to CKD in type 1 diabetes. Ongoing trials, such as FINE-ONE with finerenone, may soon expand therapeutic options and ensure no patient is left behind.

This case-based program explores the missed opportunities in CKD detection and treatment in a patient with type 2 diabetes. Drs. Agarwal and Cos emphasize the role of primary care physicians in annual UACR screening, which can reveal kidney injury long before symptoms occur. With new evidence from the CONFIDENCE and other trials, the discussion highlights the benefits and safety of early combination therapy with finerenone and SGLT2i, and GLP-1 receptor agonists. Practical strategies are shared to support primary care teams in integrating these therapies and reducing long-term cardio-kidney-metabolic risk.

On-demand webcast of expert faculty presentation on the connection between obstructive sleep apnea (OSA) and obesity, including strategies for prioritizing weight loss to improve OSA management among select patients.

Tardive Dyskinesia (TD) is an involuntary movement disorder that can develop as a side effect of taking antipsychotic and other medications. Currently there are 2 FDA approved VMAT2 inhibitors for treating TD. Join Drs. Cristoph U. Correll and Jonathan M. Meyer for this expert discussion on the most recent data presented at the Psych Congress 2025 in San Diego on VMAT2 inhibitors for the treatment of TD.

This Clinical Countdown addresses key challenges in diagnosing and managing generalized myasthenia gravis (gMG), with a focus on FcRn antagonists. Drs. Edmundson and Goyal review diagnostic challenges in gMG, along with the mechanism of FcRn blockade and how it compares to traditional therapies such as corticosteroids, IVIG, and plasma exchange. The discussion highlights pivotal phase 3 trials (ADAPT, MycarinG, and VIVACITY MG), evaluating differences in efficacy, dosing schedules, and administration routes for agents like efgartigimod, rozanolixizumab, and nipocalimab. Faculty discuss how data from these trials informs individualized treatment planning and facilitates shared decision-making.

Despite its prevalence, chronic kidney disease–associated pruritus (CKD-aP) remains underrecognized and undertreated in patients undergoing hemodialysis, owing to its complex pathophysiology, diagnostic challenges, symptom cluster etiology, and multidimensional impact on quality of life. Learn best practices from the experts, including how to use validated tools and structured approaches for assessing CKD-aP severity, and evidence-based, patient-centered treatment strategies. Using real-world case reviews, explore the value of multidisciplinary care, communication, and shared decision-making to address the physical and psychosocial complexities of CKD-aP.

Despite its prevalence, chronic kidney disease–associated pruritus (CKD-aP) remains underrecognized and undertreated in patients undergoing hemodialysis, owing to its complex pathophysiology, diagnostic challenges, symptom cluster etiology, and multidimensional impact on quality of life. Learn best practices from the experts, including how to use validated tools and structured approaches for assessing CKD-aP severity, and evidence-based, patient-centered treatment strategies. Using real-world case reviews, explore the value of multidisciplinary care, communication, and shared decision-making to address the physical and psychosocial complexities of CKD-aP.

Despite its prevalence, chronic kidney disease–associated pruritus (CKD-aP) remains underrecognized and undertreated in patients undergoing hemodialysis, owing to its complex pathophysiology, diagnostic challenges, symptom cluster etiology, and multidimensional impact on quality of life. Learn best practices from the experts, including how to use validated tools and structured approaches for assessing CKD-aP severity, and evidence-based, patient-centered treatment strategies. Using real-world case reviews, explore the value of multidisciplinary care, communication, and shared decision-making to address the physical and psychosocial complexities of CKD-aP.

Despite its prevalence, chronic kidney disease–associated pruritus (CKD-aP) remains underrecognized and undertreated in patients undergoing hemodialysis, owing to its complex pathophysiology, diagnostic challenges, symptom cluster etiology, and multidimensional impact on quality of life. Learn best practices from the experts, including how to use validated tools and structured approaches for assessing CKD-aP severity, and evidence-based, patient-centered treatment strategies. Using real-world case reviews, explore the value of multidisciplinary care, communication, and shared decision-making to address the physical and psychosocial complexities of CKD-aP.

Despite its prevalence, chronic kidney disease–associated pruritus (CKD-aP) remains underrecognized and undertreated in patients undergoing hemodialysis, owing to its complex pathophysiology, diagnostic challenges, symptom cluster etiology, and multidimensional impact on quality of life. Learn best practices from the experts, including how to use validated tools and structured approaches for assessing CKD-aP severity, and evidence-based, patient-centered treatment strategies. Using real-world case reviews, explore the value of multidisciplinary care, communication, and shared decision-making to address the physical and psychosocial complexities of CKD-aP.

Despite its prevalence, chronic kidney disease–associated pruritus (CKD-aP) remains underrecognized and undertreated in patients undergoing hemodialysis, owing to its complex pathophysiology, diagnostic challenges, symptom cluster etiology, and multidimensional impact on quality of life. Learn best practices from the experts, including how to use validated tools and structured approaches for assessing CKD-aP severity, and evidence-based, patient-centered treatment strategies. Using real-world case reviews, explore the value of multidisciplinary care, communication, and shared decision-making to address the physical and psychosocial complexities of CKD-aP.

Despite its prevalence, chronic kidney disease–associated pruritus (CKD-aP) remains underrecognized and undertreated in patients undergoing hemodialysis, owing to its complex pathophysiology, diagnostic challenges, symptom cluster etiology, and multidimensional impact on quality of life. Learn best practices from the experts, including how to use validated tools and structured approaches for assessing CKD-aP severity, and evidence-based, patient-centered treatment strategies. Using real-world case reviews, explore the value of multidisciplinary care, communication, and shared decision-making to address the physical and psychosocial complexities of CKD-aP.

Despite its prevalence, chronic kidney disease–associated pruritus (CKD-aP) remains underrecognized and undertreated in patients undergoing hemodialysis, owing to its complex pathophysiology, diagnostic challenges, symptom cluster etiology, and multidimensional impact on quality of life. Learn best practices from the experts, including how to use validated tools and structured approaches for assessing CKD-aP severity, and evidence-based, patient-centered treatment strategies. Using real-world case reviews, explore the value of multidisciplinary care, communication, and shared decision-making to address the physical and psychosocial complexities of CKD-aP.

Despite its prevalence, chronic kidney disease–associated pruritus (CKD-aP) remains underrecognized and undertreated in patients undergoing hemodialysis, owing to its complex pathophysiology, diagnostic challenges, symptom cluster etiology, and multidimensional impact on quality of life. Learn best practices from the experts, including how to use validated tools and structured approaches for assessing CKD-aP severity, and evidence-based, patient-centered treatment strategies. Using real-world case reviews, explore the value of multidisciplinary care, communication, and shared decision-making to address the physical and psychosocial complexities of CKD-aP.

This session from WHAV 2025 explores the complex interplay between hormonal changes and migraine pathophysiology in women, from menarche through menopause. Faculty review diagnostic frameworks, including ICHD-3 criteria, and emphasize menstrual migraine subtypes and the role of estrogen withdrawal. Evidence-based strategies for acute and preventive treatment are discussed, including the use of CGRP receptor antagonists, hormonal therapies, and neuromodulation devices. The program also addresses disparities in care and supports shared decision-making tailored to life stage, comorbidities, and patient preferences.

This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

On-demand webcast with expert faculty presentation highlighting key studies in diabetes from the 2025 American Diabetes Association and European Association for the Study of Diabetes annual meetings.

This dynamic symposium will guide clinicians through a modern, patient-centered approach to endometriosis care. Faculty will explore how early diagnosis can improve physical and psychosocial outcomes, examine tools to advance equity and shared decision-making, and evaluate the latest evidence for GnRH antagonists as a nonsurgical treatment strategy. The session concludes with a patient perspective that illustrates how lived experience can inform more patient-centered, multidisciplinary care that incorporates medical treatment and shared decision-making.

Hypertrophic cardiomyopathy (HCM) management is being transformed by advances in diagnostics and the emergence of targeted therapies. In this program, leading international experts review challenges in early recognition, the evolving role of beta-blockers and traditional therapies, and the clinical impact of novel cardiac myosin inhibitors. Data from pivotal studies—including the landmark MAPLE-HCM trial—are examined in depth, with a focus on exercise capacity, gradient reduction, biomarkers, and patient outcomes. Faculty also share practical strategies for patient selection, monitoring, and translating trial evidence into daily cardiology practice.

Presented at the 21st Annual Women’s Health Annual Visit (WHAV 2025), this session reviews strategies for diagnosing and treating irritable bowel syndrome (IBS), with a focus on distinguishing IBS-C from IBS-D. Faculty explore the burden of disease, stigma, and the importance of a positive diagnostic strategy using Rome IV criteria, supported by history, physical examination, and selective testing. Treatment approaches include lifestyle changes, pharmacologic interventions, and brain-gut behavioral therapies.

This WHAV 2025 session addresses obstructive sleep apnea (OSA) in women, highlighting how phenotype and risk factors shift across life stages. Experts discuss how varying phenotypes contribute to delayed diagnosis and review screening tools, referral strategies, evidence linking OSA to cardiometabolic risks in menopause and pregnancy and available treatment options. The program underscores the importance of a precision medicine approach informed by phenotype, hormonal status, and patient goals at each stage of a woman’s life.

Join Drs. An de Vriese and Muh Geot Wong in a case-based discussion on optimizing long-term kidney outcomes in patients with IgA nephropathy (IgAN). Faculty review the new KDIGO guidelines, including more aggressive treatment targets such as proteinuria levels below 0.3 g/day. A clinical case is used to illustrate practical guideline application, highlighting the use of sparsentan in a patient with persistent proteinuria despite RAASi therapy. The faculty also explore combination treatment approaches, including SGLT2 inhibitors, and reference data from the SPARTAN and SPARTACUS studies.

Join Drs. Scott Solomon and John McMurray as they examine the new indication for finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in treating patients with heart failure with LVEF ≥40%. Drawing on data from the FINEARTS-HF trial, faculty discuss patient selection, dosing considerations based on renal function, and the additive benefits of combining finerenone with SGLT2 inhibitors. A clinical case illustrates typical comorbidities—atrial fibrillation, hypertension, and diabetes—and how finerenone may address multiple cardiovascular and metabolic risks.

This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the role of biomarker testing, including PD-L1 CPS and CLDN18.2, in guiding therapeutic decisions. Key clinical trial data on anti-PD-1 therapies such as nivolumab, pembrolizumab, and tislelizumab are discussed, along with regimen-specific adverse event profiles. Patient case examples illustrate the application of guideline-based treatment selection utilizing biomarker status in clinical practice.

This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the role of biomarker testing, including PD-L1 CPS and CLDN18.2, in guiding therapeutic decisions. Key clinical trial data on anti-PD-1 therapies such as nivolumab, pembrolizumab, and tislelizumab are discussed, along with regimen-specific adverse event profiles. Patient case examples illustrate the application of guideline-based treatment selection utilizing biomarker status in clinical practice.

This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the role of biomarker testing, including PD-L1 CPS and CLDN18.2, in guiding therapeutic decisions. Key clinical trial data on anti-PD-1 therapies such as nivolumab, pembrolizumab, and tislelizumab are discussed, along with regimen-specific adverse event profiles. Patient case examples illustrate the application of guideline-based treatment selection utilizing biomarker status in clinical practice.

This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the role of biomarker testing, including PD-L1 CPS and CLDN18.2, in guiding therapeutic decisions. Key clinical trial data on anti-PD-1 therapies such as nivolumab, pembrolizumab, and tislelizumab are discussed, along with regimen-specific adverse event profiles. Patient case examples illustrate the application of guideline-based treatment selection utilizing biomarker status in clinical practice.

Can you recognize the symptoms of major depressive disorder? Do you know when to augment and when to switch therapies? Join our experts for these answers and learn about novel treatments on the horizon. Don’t miss this opportunity to enhance your clinical practice and positively impact the lives of your patients.

This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Participants will gain practical insights on selecting appropriate patients for B7-H3 ADCs, including efficacy and safety considerations. The program will equip oncology professionals with evidence-based strategies to integrate emerging B7-H3 ADCs into multidisciplinary care for ES-SCLC when they become available.

*Episodes 1–3 were posted pre-ESMO on 9/26, and Episodes 4–6 were posted post-ESMO on 11/11.

This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Participants will gain practical insights on selecting appropriate patients for B7-H3 ADCs, including efficacy and safety considerations. The program will equip oncology professionals with evidence-based strategies to integrate emerging B7-H3 ADCs into multidisciplinary care for ES-SCLC when they become available.

*Episodes 1–3 were posted pre-ESMO on 9/26, and Episodes 4–6 were posted post-ESMO on 11/11.

This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Participants will gain practical insights on selecting appropriate patients for B7-H3 ADCs, including efficacy and safety considerations. The program will equip oncology professionals with evidence-based strategies to integrate emerging B7-H3 ADCs into multidisciplinary care for ES-SCLC when they become available.

*Episodes 1–3 were posted pre-ESMO on 9/26, and Episodes 4–6 were posted post-ESMO on 11/11.

This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Participants will gain practical insights on selecting appropriate patients for B7-H3 ADCs, including efficacy and safety considerations. The program will equip oncology professionals with evidence-based strategies to integrate emerging B7-H3 ADCs into multidisciplinary care for ES-SCLC when they become available.

*Episodes 1–3 were posted pre-ESMO on 9/26, and Episodes 4–6 were posted post-ESMO on 11/11.

This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Participants will gain practical insights on selecting appropriate patients for B7-H3 ADCs, including efficacy and safety considerations. The program will equip oncology professionals with evidence-based strategies to integrate emerging B7-H3 ADCs into multidisciplinary care for ES-SCLC when they become available.

*Episodes 1–3 were posted pre-ESMO on 9/26, and Episodes 4–6 were posted post-ESMO on 11/11.

This online CME program will provide the latest clinical updates on B7-H3–directed antibody-drug conjugates (ADCs) in extensive-stage small cell lung cancer (ES-SCLC). Faculty experts will review the biological rationale for targeting B7-H3 in ES-SCLC and discuss recent clinical evidence on B7-H3 ADCs presented at WCLC and ESMO 2025. Participants will gain practical insights on selecting appropriate patients for B7-H3 ADCs, including efficacy and safety considerations. The program will equip oncology professionals with evidence-based strategies to integrate emerging B7-H3 ADCs into multidisciplinary care for ES-SCLC when they become available.

*Episodes 1–3 were posted pre-ESMO on 9/26, and Episodes 4–6 were posted post-ESMO on 11/11.

Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRA) use due to hyperkalemia concerns. Using a multidisciplinary approach, experts in cardiology and nephrology address the clinical implications of suboptimal RAASi and MRA use, compare real-world data on the efficacy and safety of oral potassium binders, and developing evidence-based treatment strategies that incorporate potassium binders to improve outcomes in patients with CKD and HF who are at risk for or experiencing hyperkalemia.

Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRA) use due to hyperkalemia concerns. Using a multidisciplinary approach, experts in cardiology and nephrology address the clinical implications of suboptimal RAASi and MRA use, compare real-world data on the efficacy and safety of oral potassium binders, and developing evidence-based treatment strategies that incorporate potassium binders to improve outcomes in patients with CKD and HF who are at risk for or experiencing hyperkalemia.

Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRA) use due to hyperkalemia concerns. Using a multidisciplinary approach, experts in cardiology and nephrology address the clinical implications of suboptimal RAASi and MRA use, compare real-world data on the efficacy and safety of oral potassium binders, and developing evidence-based treatment strategies that incorporate potassium binders to improve outcomes in patients with CKD and HF who are at risk for or experiencing hyperkalemia.

Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRA) use due to hyperkalemia concerns. Using a multidisciplinary approach, experts in cardiology and nephrology address the clinical implications of suboptimal RAASi and MRA use, compare real-world data on the efficacy and safety of oral potassium binders, and developing evidence-based treatment strategies that incorporate potassium binders to improve outcomes in patients with CKD and HF who are at risk for or experiencing hyperkalemia.

Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRA) use due to hyperkalemia concerns. Using a multidisciplinary approach, experts in cardiology and nephrology address the clinical implications of suboptimal RAASi and MRA use, compare real-world data on the efficacy and safety of oral potassium binders, and developing evidence-based treatment strategies that incorporate potassium binders to improve outcomes in patients with CKD and HF who are at risk for or experiencing hyperkalemia.

Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRA) use due to hyperkalemia concerns. Using a multidisciplinary approach, experts in cardiology and nephrology address the clinical implications of suboptimal RAASi and MRA use, compare real-world data on the efficacy and safety of oral potassium binders, and developing evidence-based treatment strategies that incorporate potassium binders to improve outcomes in patients with CKD and HF who are at risk for or experiencing hyperkalemia.

Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRA) use due to hyperkalemia concerns. Using a multidisciplinary approach, experts in cardiology and nephrology address the clinical implications of suboptimal RAASi and MRA use, compare real-world data on the efficacy and safety of oral potassium binders, and developing evidence-based treatment strategies that incorporate potassium binders to improve outcomes in patients with CKD and HF who are at risk for or experiencing hyperkalemia.

Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRA) use due to hyperkalemia concerns. Using a multidisciplinary approach, experts in cardiology and nephrology address the clinical implications of suboptimal RAASi and MRA use, compare real-world data on the efficacy and safety of oral potassium binders, and developing evidence-based treatment strategies that incorporate potassium binders to improve outcomes in patients with CKD and HF who are at risk for or experiencing hyperkalemia.

Patients with chronic kidney disease (CKD) and heart failure with reduced ejection fraction (HFrEF) will achieve improved benefits from optimized use of guideline directed medical therapy, however healthcare providers may not be utilizing renin–angiotensin aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRA) use due to hyperkalemia concerns. Using a multidisciplinary approach, experts in cardiology and nephrology address the clinical implications of suboptimal RAASi and MRA use, compare real-world data on the efficacy and safety of oral potassium binders, and developing evidence-based treatment strategies that incorporate potassium binders to improve outcomes in patients with CKD and HF who are at risk for or experiencing hyperkalemia.

Bronchiectasis is complex, often underdiagnosed, and frequently misunderstood. Explore key contributors to disease progression, including the role of neutrophilic inflammation and neutrophilic serine proteases, and learn to distinguish bronchiectasis from other respiratory conditions and assess patient risk factors that impact outcomes. This module covers how pulmonary exacerbations influence disease course and highlights new insights from recent clinical trials. Stay ahead of the curve with updates on emerging therapies that could transform how we manage this challenging disease.

This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

This CME activity focuses on multiwavelength photobiomodulation (PBM), an emerging therapy indicated for the treatment of dry age-related macular degeneration (AMD). Hear from leading researchers and retina specialists about the mechanism of action, how it is administered, its efficacy and safety profile, therapeutic durability, which patients may benefit the most, and how PBM would fit into the AMD treatment paradigm.

On-demand webcast of expert faculty presentation on the key connection between psoriasis and obesity, including comprehensive treatment strategies that consider outcomes improvement for both diseases.

Chronic rhinosinusitis with nasal polyps (CRSwNP) presents a large burden on more than 3 million patients with the conditions — especially when intertwined with asthma and allergy. Join our discussion between patients with CRSwNP and leading experts in ENT, allergy, and pulmonary medicine as they:

• Breakdown how to recognize key inflammatory patterns.
• Discuss the burden of illness and goals of treatment
• Interpret clinical trial data on biologic treatments.
• Apply a collaborative care approach to improve patient outcomes.

Watch now to explore cases with patient panelists, expert perspectives, and evidence-based strategies for managing CRSwNP in multidisciplinary settings.

Need to catch up on the latest data surrounding next-generation retinal treatments? Drs. Veeral Sheth and Durga Borkar walk through the most recent efficacy and safety data around faricimab, aflibercept 8 mg, and the PDS with ranibizumab. They also review the latest insights on the use of these treatments in real-world practice.

Wondering how your practice’s use of next-generation retinal agents compares to the experts? Join Dr. Durga Borkar and Dr. Veeral Sheth as they discuss how they are using next-generation agents to free their patients from frequent office visits.

Join our experts as they examine the integration of perioperative immune checkpoint inhibitors (ICIs) in the management of resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC). Drs. Le Tourneau and Harrington discuss unmet needs and limitations of current treatment and review data from trials supporting the use of perioperative ICIs, emphasizing their event-free survival and pathologic response outcomes. The conversation also addresses multidisciplinary coordination and considerations for managing immune-related adverse events. Variations in treatment guidelines, access, and clinical practice between the US, Europe, and other regions are explored to contextualize the challenges of global implementation and provide strategies for practitioners to improve care.

Neuropsychiatric symptoms (NPS) associated with Alzheimer’s disease (AD), such as psychosis and agitation, affect up to 50% of individuals with AD yet remain underdiagnosed and undertreated in clinical practice. These symptoms accelerate cognitive decline, increase mortality risk, and substantially worsen patient and caregiver quality of life. This broadcast replay will provide a practical and engaging discussion of the underlying pathophysiology of NPS associated with AD, the limitations of off-label antipsychotic use, and emerging therapeutic agents targeting NPS associated with AD.

Learn about emerging data in transthyretin amyloid cardiomyopathy (ATTR-CM) from recent congresses, journal publications, and retrospective database analysis, with practical guidance on integrating these findings into clinical practice to inform treatment strategies and patient management. Findings include reduced atrial fibrillation events and lower rates of cardiovascular hospitalization and all-cause mortality from the Heart Failure Association of the ESC. In addition, a recent publication highlights early and sustained increases in serum transthyretin (TTR) levels that are independently associated with improved survival. Additional insights are drawn from the UK Biobank database, showing that lower TTR levels are linked with a higher burden of chronic comorbidities.

In this episode of Clinical Countdown, Professors Jonathan Barratt and Sydney Tang discuss the evolving treatment strategies for IgA nephropathy, focusing on lowering proteinuria through combination therapy. They examine differences in disease presentation across global populations and emphasize updated KDIGO guidance on aggressive proteinuria reduction targets. The discussion includes evidence from the PROTECT trial supporting sparsentan’s efficacy as a dual endothelin–angiotensin receptor antagonist and considers the role of SGLT2 inhibitors based on outcomes from the DAPA-CKD and EMPA-KIDNEY trials. Our experts also review recent real-world data showing that when added to SGLT2 inhibitors and RAS blockade, sparsentan can significantly reduce proteinuria without notable safety concerns.

Join our expert panel as they explore the evolving treatment landscape of resectable locally advanced head and neck squamous cell carcinoma. Learn how perioperative immune checkpoint inhibitors are improving event-free survival and get practical insights on applying this data to clinical care. The discussion highlights the importance of early multidisciplinary collaboration and offers perspectives on patient selection, treatment timing, and managing adverse events. Don’t miss this opportunity to enhance your approach to reducing recurrence and disease progression in your patients.

This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

This online CME activity examines advances in managing resectable locally advanced head and neck squamous cell carcinoma (HNSCC), focusing on the integration of perioperative immune checkpoint inhibitors (ICIs) and multimodal approaches. Faculty review current standards of care and highlight unmet needs that have driven investigation into combining radiation and immunotherapy. Emerging clinical trial data are discussed, including the impact of perioperative ICIs on event-free survival and pathologic response, with attention to patient selection informed by risk stratification and biomarkers. The program also addresses practical considerations for multidisciplinary care, including immune-related adverse event management and strategies to support patient access to these evolving treatment paradigms.

Subcutaneously-administered GLP-1 RAs have demonstrated cardiovascular and renal risk reduction in individuals with type 2 diabetes at high ASCVD risk; they are recommended in the 2025 ADA Standards of Care as part of the comprehensive approach to cardiovascular and kidney risk reduction. Many individuals with type 2 diabetes are reluctant to initiate or refuse injectable therapy. Oral GLP-1 RA therapy has demonstrated robust reductions in A1C and in body weight; in addition, the cardiovascular safety of oral GLP-1 RA therapy has been established in individuals with T2D and high cardiovascular risk. Until recently, there has been an unmet need to determine the cardiovascular efficacy of this oral therapy in patients at high cardiovascular risk—for example, in those individuals with ASCVD, CKD, or both. Dr. Silvio Inzucchi and Dr. Darren McGuire will review trials with injectable GLP-1 RAs in individuals with T2D and high ASCVD risk, and discuss the recent clinical trial evidence in this population with oral GLP-1 RA therapy and the implications for patient management.

Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.

Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.

Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.

Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.

Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.

Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.

Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.

Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents across lines of therapy and how they contribute to improved adherence and survival outcomes.

Acromegaly, a rare endocrine disorder caused by excessive growth hormone (GH) secretion, has a profound impact on affected individuals and healthcare systems. Patients often experience delays in diagnosis, averaging 4 to 6 years, which exacerbates disease progression and leads to irreversible comorbidities. Do you know how to effectively treat acromegaly to increase your patients’ quality of life? Tune in for an overview of the latest data.

This brief clinical discussion examines findings presented at the ESC Heart Failure 2025 meeting in Belgrade, Serbia, on the impact of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM). The analysis highlights a reduction in atrial fibrillation events and an improvement in cardiovascular outcomes among patients treated with acoramidis, including those with both wild-type and variant transthyretin (TTR). Data from the ATTRibute-CM study are reviewed, showing associations between treatment and increased serum TTR levels, delayed time to first cardiovascular hospitalization, reduced NT-proBNP levels, and lower all-cause mortality. These results suggest a clinically meaningful benefit of acoramidis and support its potential role in managing ATTR-CM.

Join Dr. Aristides Maniatis for this Patient-Clinician Connection, a case-based activity that explores the full spectrum of care in Growth Hormone Deficiency. Through real patient and caregiver dialogues, this program teaches clinicians how to identify early signs of GHD, make accurate diagnoses, navigate pediatric-to-adult care transitions, and manage the switch from daily to long-acting growth hormone therapy. Grounded in real-life experiences and expert insights, this activity delivers practical strategies for fostering patient-centered care and improving outcomes across every stage of the GHD journey

Perioperative immunotherapy has evolved into a novel therapeutic strategy for early-stage, resectable NSCLC, maximizing the efficacy of immunotherapy when the primary tumor is still present with a high neoantigen burden. Perioperative immunotherapy also allows the use of preoperative pathology as a guide for postoperative care and offers a pathway to potential surgical intervention due to tumor shrinkage for those who are not initially eligible for surgery. Clarifying the rationale behind perioperative immunotherapy in this context is crucial for optimizing treatment strategies and outcomes.

The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).

The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).

The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).

The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).

The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).

The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).

The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).

The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).

The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is essential to delivering optimal care—but also increasingly challenging. This microlearning-based activity is designed to distill key clinical topics in a unique and digestible manner that can be easily integrated into a busy clinician’s schedule. This activity will enable providers to engage in succinct, faculty-driven discussions addressing current gaps related to the diagnosis and individualized management of patients with early and advanced non-small cell lung cancer (NSCLC) as well as limited- and extensive-stage small cell lung cancer (SCLC).

This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN^®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCN Guideline^® recommendations.

*This program was published on July 31st, 2025 and the information therein was up-to-date when created.

This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN^®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCN Guideline^® recommendations.

*This program was published on July 31st, 2025 and the information therein was up-to-date when created.

This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN^®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCN Guideline^® recommendations.

*This program was published on July 31st, 2025 and the information therein was up-to-date when created.

This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN^®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCN Guideline^® recommendations.

*This program was published on July 31st, 2025 and the information therein was up-to-date when created.

This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN^®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCN Guideline^® recommendations.

*This program was published on July 31st, 2025 and the information therein was up-to-date when created.

This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN^®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCN Guideline^® recommendations.

*This program was published on July 31st, 2025 and the information therein was up-to-date when created.

This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN^®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCN Guideline^® recommendations.

*This program was published on July 31st, 2025 and the information therein was up-to-date when created.

This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN^®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCN Guideline^® recommendations.

*This program was published on July 31st, 2025 and the information therein was up-to-date when created.

This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN^®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCN Guideline^® recommendations.

*This program was published on July 31st, 2025 and the information therein was up-to-date when created.

This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN^®), focuses on translating oncology clinical practice guidelines into practical strategies for treating melanoma. Participants will learn how to integrate clinical trial data into guideline-concordant treatment plans in the neoadjuvant, adjuvant, and metastatic settings. The program highlights the importance of evidence-based approaches and the use of immunotherapy for the treatment of melanoma. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic tactics aligned with NCCN Guideline^® recommendations.

*This program was published on July 31st, 2025 and the information therein was up-to-date when created.

This three-part panel series explores how emerging evidence from the CONFIDENCE trial is shaping the future of cardio-kidney-metabolic (CKM) care. In Chapter 1, the experts discuss the additive benefits and safety of combining a nonsteroidal MRA and an SGLT2 inhibitor. Chapter 2 focuses on patient selection and individualized strategies for initiating combination therapy. Chapter 3 shifts to real-world implementation, highlighting multidisciplinary collaboration and strategies to improve adherence and continuity of care. Together, this series provides a roadmap to optimize outcomes in patients with CKD and T2D.

In this Virtual Case Clinic, explore three patient case examples with Dr. Mahtani as she demonstrates the application of the latest clinical evidence in HER2-positive, HER2-low, and HER2-ultralow metastatic breast cancer. By illustrating the use of antibody-drug conjugates in HER2-expressing disease, participants will gain insights into optimal evidence-based treatment selection based upon HER2 expression.

Our experts, Drs. Robert Motzer and Elizabeth Plimack, discuss first-line treatment strategies for advanced renal cell carcinoma in a community clinic setting. Drawing from pivotal clinical trials and guideline recommendations, they highlight how to personalize therapy based on IMDC risk stratification and patient characteristics. Practical decision-making in both intermediate- and poor-risk disease is examined through 2 detailed patient cases, with an emphasis on outcomes, therapy sequencing, and real-world considerations. The discussion also addresses immune-related and TKI-associated adverse events and outlines monitoring and management strategies that support patient safety and treatment continuity. Tune in for expert reflections on integrating evolving data into daily oncology practice.

This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.

Review findings from the UK Biobank presented recently at the Peripheral Nerve Society meeting, revealing that naturally low transthyretin (TTR) levels are associated with a higher prevalence of cardiovascular biomarkers, such as NT-proBNP, and comorbidities, including peripheral arterial disease, stroke, and cognitive decline. The data suggest that low TTR may serve as a marker of broader systemic illness, both in patients with TTR amyloidosis and in the general population.

The CONFIDENCE trial shows that combining an SGLT2 inhibitor with finerenone cuts albuminuria by more than 50% in patients with chronic kidney disease and type 2 diabetes. In this video, 2 nephrologists discuss how they apply these insights in clinical practice. A compelling real-world case highlights the power of 4-pillar therapy to optimize cardio-renal outcomes. Tune in to see how modern treatment strategies are transforming patient care.

This online chapterized CME activity features Drs. Kevin Kalinsky and Komal Jhaveri in a discussion on TROP2-targeted antibody-drug conjugates (ADCs) for metastatic breast cancer (mBC). The faculty describe the therapeutic role of TROP2 as well as both approved and investigational ADCs that target TROP2. Clinical trial data on TROP2-targeted ADCs from various studies are reviewed to evaluate their efficacy and safety across hormone receptor–positive and triple-negative disease settings. The discussion contrasts molecular structures, dosing schedules, and toxicity profiles of each ADC, providing insight into their positioning in treatment algorithms. Practical strategies for therapy sequencing, patient selection, and shared decision-making are emphasized throughout.

Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

Managing patients with pulmonary arterial hypertension, or PAH, can present certain challenges. PAH is a serious, progressive condition, and its effective management involves the consideration of several factors to meet treatment goals. The utilization of patient-reported outcome measures (PROMs) to enhance shared decision-making can be a valuable tool to help integrate lifestyle, palliative care, and patient goals into a PAH care plan and address diverse and global needs.

By completing this activity, learners will gain the skills and confidence to determine therapeutic candidacy and conduct appropriate assessments for patients with Duchenne Muscular Dystrophy (DMD) across the age spectrum, including older and non-ambulatory individuals. They will improve their ability to interpret and apply the latest clinical data to real-world scenarios and make informed decisions about treatment and monitoring. Through case-based education, learners will enhance their competence in aligning patients to appropriate therapies and managing long-term care in a rapidly evolving treatment landscape.

This 30-minute Chairperson’s Perspective program explores the evolving landscape of (epidermal growth factor receptor) EGFR-altered metastatic non–small cell lung cancer through guideline-concordant, evidence-based learning. Dr. Natasha Leighl reviews the clinical importance and optimal timing of molecular testing and provides evidence-based strategies for patient selection and treatment sequencing across EGFR mutation subtypes, including common mutations and exon 20 insertions. Emphasis will be placed on emerging therapies, key clinical trial data, and the integration of multidisciplinary care in managing adverse events associated with EGFR-targeted therapies.

This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.

This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.

This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.

This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.

This series of bite-sized episodes contains important information on using vagus nerve stimulation (VNS) for the treatment of drug-resistant epilepsy (DRE) and treatment-resistant depression (TRD). Drs. Raman Sankar and Scott Aaronson discuss best practices for identifying and treating patients as well as programming strategies for VNS.

The epidemic of metabolic dysfunction-associated liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) is fully upon the US healthcare system, and it's projected to get worse. The prevalence of MASLD in the US is expected to increase from 33.7% in 2020 to 41.4% in 2050, which translates to approximately 122 million adults being affected. Our broadcast on Global Fatty Liver Day provides practical and engaging discussions to help endocrinologists and primary care providers better understand the use of noninvasive tests and biomarkers for timely screening and primary risk assessment, treatment and management of cardiometabolic risk, and assignment to the appropriate level of care for patients with MASLD/MASH.

Pulmonary hypertension (PH) is a serious, progressive condition and the care pathways for patients who are living with Group 1 versus Group 2 PH can be very different. Join our experts as they discuss key elements for identifying which WHO Group your patient may fall into and review key factors for developing an effective treatment plan and knowing when to refer patients to other professionals that are part of the PH care team.

Pulmonary arterial hypertension (PAH) is a serious, progressive condition that involves making the correct diagnosis and identifying patient comorbidities as important first steps to creating a successful treatment approach. And while identifying which WHO Group a patient belongs to is key, part of the art of treating PAH is recognizing that many patients can have overlap between groups. Our experts’ insights can help you elevate your practice and develop effective PAH treatment plans.

Pulmonary arterial hypertension (PAH) is a serious, progressive condition and successfully managing patients can present certain challenges. Treatment selection is multifactorial and often involves the consideration of myriad patient factors, including WHO Group, objective risk stratification score, cardiac functioning on imaging, and shared decision-making. And while all patients who are living with PAH require careful evaluation, those with comorbidities and/or psychosocial challenges can require additional consideration when developing a treatment plan that improves outcomes.

Heart failure with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) represent a significant and growing burden for patients and the healthcare system, not only in cardiovascular medicine, but also in the context of cardio-kidney-metabolic (CKM) syndrome. Trials are underway evaluating new therapies that may offer benefits to patients with HFmrEF/HFpEF and may also have broader, multisystem effects. Tune in to stay up to date!

Designed as a dynamic, intensive, and innovative web-based activity, this session will take learners on an in-depth exploration of cancer-related anemia (CRA) and chemotherapy-induced anemia (CIA) as disease states of vast clinical significance, emphasizing the robust prevalence, pathophysiology, and patient burden of CRA/CIA, as well as the prominent role of iron deficiency (ID) in their pathogenesis. Built upon on this foundation, expert faculty will guide attendees through a succinct but comprehensive review of the IV iron evidentiary base in CRA/CIA, including clinical trials, systematic reviews and meta-analyses, and the latest expert consensus guideline recommendations from the NCCN, ASCO/ASH, and ESMO. Practical clinical pearls for safely and effectively implementing IV iron into the real-world hematology/oncology clinic will be emphasized.

Listen to Dr. Riccardo Inciardi’s summary from the ESC Preventive Cardiology 2025 meeting, where he highlights new therapies reshaping the management of cardio-kidney-metabolic (CKM) syndrome and heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Watch as he breaks down the latest clinical trial data showing that SGLT2 inhibitors, GLP-1 receptor agonists, and the nonsteroidal MRA finerenone can meaningfully reduce hospitalizations, kidney disease progression, and cardiovascular mortality. A real-life patient case illustrates how combining these therapies—under the care of a multidisciplinary team—can transform outcomes.

Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

Irritable bowel syndrome with constipation (IBS-C) significantly impacts patients, not only with its physical symptoms of persistent constipation, abdominal pain, and bloating, but also through a considerable psychological and social burden. Do you know how to effectively treat IBS-C to increase your patients’ quality of life? Tune in for an overview of the latest data.

These video briefs feature expert commentary on the latest clinical data presented at ERA 2025 and highlight finerenone’s evolving role in the care of patients with the cardio-kidney-metabolic syndrome. Specialists discuss new findings from the CONFIDENCE trial and FINEARTS-HF trial, including the efficacy and safety of combining finerenone with SGLT2 inhibitors, finerenone’s impact on eGFR slope across albuminuria levels, and the prognostic significance of albuminuria reduction. The series delves into the mechanistic rationale, therapeutic implications, and real-world potential of nonsteroidal MRAs in managing patients with chronic kidney disease, type 2 diabetes, and heart failure. Viewers will gain practical insights on integrating these data into their clinical practice to improve patient outcomes.

These video briefs feature expert commentary on the latest clinical data presented at ERA 2025 and highlight finerenone’s evolving role in the care of patients with the cardio-kidney-metabolic syndrome. Specialists discuss new findings from the CONFIDENCE trial and FINEARTS-HF trial, including the efficacy and safety of combining finerenone with SGLT2 inhibitors, finerenone’s impact on eGFR slope across albuminuria levels, and the prognostic significance of albuminuria reduction. The series delves into the mechanistic rationale, therapeutic implications, and real-world potential of nonsteroidal MRAs in managing patients with chronic kidney disease, type 2 diabetes, and heart failure. Viewers will gain practical insights on integrating these data into their clinical practice to improve patient outcomes.

These video briefs feature expert commentary on the latest clinical data presented at ERA 2025 and highlight finerenone’s evolving role in the care of patients with the cardio-kidney-metabolic syndrome. Specialists discuss new findings from the CONFIDENCE trial and FINEARTS-HF trial, including the efficacy and safety of combining finerenone with SGLT2 inhibitors, finerenone’s impact on eGFR slope across albuminuria levels, and the prognostic significance of albuminuria reduction. The series delves into the mechanistic rationale, therapeutic implications, and real-world potential of nonsteroidal MRAs in managing patients with chronic kidney disease, type 2 diabetes, and heart failure. Viewers will gain practical insights on integrating these data into their clinical practice to improve patient outcomes.

These video briefs feature expert commentary on the latest clinical data presented at ERA 2025 and highlight finerenone’s evolving role in the care of patients with the cardio-kidney-metabolic syndrome. Specialists discuss new findings from the CONFIDENCE trial and FINEARTS-HF trial, including the efficacy and safety of combining finerenone with SGLT2 inhibitors, finerenone’s impact on eGFR slope across albuminuria levels, and the prognostic significance of albuminuria reduction. The series delves into the mechanistic rationale, therapeutic implications, and real-world potential of nonsteroidal MRAs in managing patients with chronic kidney disease, type 2 diabetes, and heart failure. Viewers will gain practical insights on integrating these data into their clinical practice to improve patient outcomes.

Medical devices such as Barostim – or baroreflex activation therapy (BAT) – can play an important role in improving the quality of life and providing symptom relief for patients with heart failure with reduced ejection fraction, or HFrEF. NPs and nurses are key members of the healthcare team who identify patients as potential candidates for this therapy, due in large part to their expertise in eliciting symptoms and getting the full picture from patients regarding the impact of HFrEF on their quality of life. As the direct – and oftentimes most frequent – point of contact for patients, advanced care and allied health professionals can lead the way to open and honest communication with the goal of optimizing treatment plans and positively impacting patient outcomes.

Can combining a nonsteroidal MRA and an SGLT2 inhibitor unlock new clinical potential for patients with type 2 diabetes and chronic kidney disease (CKD)? In this expert discussion, Dr. Jennifer Green and Dr. Hiddo Heerspink review the latest findings from the CONFIDENCE trial, which demonstrated a significant additive reduction in albuminuria—an important surrogate marker for kidney and cardiovascular risk—when finerenone and empagliflozin are used together. They explore the clinical rationale behind combination therapy, address persistent challenges in CKD detection, and consider the practical implications for implementing these therapies in high-risk populations.

Focal segmental glomerulosclerosis (FSGS) is a prominent cause of kidney failure globally, necessitating dialysis for patient survival as the disease progresses. However, the current absence of FDA-approved treatments tailored specifically for treating adult and pediatric patients with FSGS poses a significant challenge to effectively managing this disease. Moreover, it is imperative for nephrologists to enhance their skills to implement practical strategies that improve the diagnostic approach for suspected FSGS cases, especially considering the profound impact of FSGS on patients' quality of life. This activity has been designed to provide practical guidance for the accurate diagnosis of FSGS and appropriate treatment selection, as well as to offer an expert assessment of the clinical trial data supporting emerging therapies in this setting.

Join Drs. John McMurray and Faiez Zannad as they explore the evolving role of MRAs in heart failure management. From RALES and TOPCAT to the recent FINEARTS-HF trial, they highlight key findings that shape how steroidal and nonsteroidal MRAs are used in clinical practice. Discover how the nonsteroidal MRA finerenone is expanding treatment options for patients with HFmrEF and HFpEF.

There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.

This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org

This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.

This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org

This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.

This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org

This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.

This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org

This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.

This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org

This online CME program features expert discussions on new research presented at AUA 2025. Drs. Neal Shore and Sarah Psutka explore emerging data on treatment strategies for high-risk BCG-naïve and BCG-unresponsive non–muscle invasive bladder cancer (NMIBC). They also highlight advances in biomarker-directed therapies, including investigational agents targeting HER2 and FGFR alterations. The program emphasizes the clinical relevance and practical application of these findings, offering clinicians actionable insights on evolving bladder cancer care.

Stay at the forefront of nccRCC care by exploring the latest advances in treatment strategies. Gain key insights into optimizing patient selection, enhancing diagnostic accuracy, and managing adverse events to improve patient outcomes. This comprehensive activity delves into emerging data, the rationale for ICI/TKI combination therapy, the latest clinical trial findings, and best practices for treatment sequencing. Take action today to refine your approach and deliver the best possible care for your patients.

Explore the latest treatment options, age-specific management strategies, and clinical trial data for patients with Duchenne muscular dystrophy (DMD). Through expert-led discussions and real-world patient cases, you’ll gain practical insights to help you confidently navigate today’s ever-evolving treatment landscape and deliver personalized, informed care.

Join experts, Fernanda P. Silveira, MD, MS, FIDSA, FAST and Jennifer Saullo, MD, PharmD, FIDSA, as they delve into the complexities of cytomegalovirus (CMV) prevention and treatment following solid organ transplantation (SOT). Presentations will feature detailed case discussions with a focus on managing resistant and refractory disease, addressing treatment-related toxicities, and optimizing therapeutic strategies. This program is an essential primer on the scientific challenges and solutions in this critical area of transplant medicine.

Traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial for many patients in the short term but often come with unacceptable side effects. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) has created a groundbreaking paradigm shift in our approach to both the short- and longer-term management of affected patients. Join Drs. Vera Bril and Neelam Goyal as they take a deep dive into this topic and discuss how FcRn inhibitors are changing the therapeutic landscape of gMG.

Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.

Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.

Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.

Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.

Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.

Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.

Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.

Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.

Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.

Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder characterized by hemolytic anemia and associated with thrombophilia and bone marrow failure. Early and accurate diagnosis and classification of PNH is essential to optimize outcomes. However, the diagnosis of PNH may be delayed or missed for months or even years in practice, and only 25% of newly diagnosed patients receive any PNH-specific treatment. Moreover, up to 20% of patients treated with C5 inhibitors continue to experience clinically significant extravascular hemolysis, leading to residual anemia and its complications. Thus, several new and novel complement inhibitors have been developed and approved. In this activity, Dr. Carlos de Castro reviews the diagnostic criteria for PNH and best practices for the selection of optimal treatment regimens.

The recent approvals of therapies for hormone-receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (MBC) have augmented the treatment armamentarium in this setting, giving clinicians more options for their patients. However, it may be challenging to select the optimal therapy for individual patients. Moreover, it is important to differentiate between the 2 available TROP2-directed antibody-drug conjugates (ADCs). This activity reviews challenges in treating HR+, HER2- MBC, the role of TROP2-directed ADCS, and how to tailor therapy for individual patients.

This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

With at least 4 percent of patients who experience COVID-19 developing long COVID, improving care for post-infectious chronic conditions is critical. By prioritizing research and education on the rheumatological effects of acute infections, we can address these patients’ unmet needs. Join Dr. Leonard Calabrese, Vice Chairman of the Department of Rheumatic and Immunologic Disease and Head of Clinical Immunology at the Cleveland Clinic Foundation, as he explains what we know so far about these conditions.

The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.

The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.

The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.

The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.

The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.

The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.

The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) can lead to substantial medical challenges for the mother, fetus, and neonate. Diagnosis is often difficult without low platelet counts or frank bleeding. But a mother’s risk for FNAIT can be assessed, and existing and newly emerging therapies can act as preventive measures and improve fetus/neonate outcomes. Join Drs. Karin Blakemore and Emilie Vander Haar as they address many of the issues surrounding the management of FNAIT and offer clear and actionable suggestions for you to bring into your clinical practice.

A paradigm change is occurring in the diagnosis and management of endometriosis. This change will help facilitate the earlier diagnosis of endometriosis and promote more widespread use of medical therapy as opposed to surgery for many women. Accompanying this change will be a more patient-centric approach to care, as well as increased efforts to diminish the impact of healthcare disparities experienced by many women during their endometriosis journey. Join our faculty, Drs. Ayman Al-Hendy, Linda Bradley, Sawsan As-Sanie, Melissa Simon, James Simon, and Lee Shulman, as they address these many issues, with a focus on improving short- and long-term patient outcomes for women with endometriosis.

A paradigm change is occurring in the diagnosis and management of endometriosis. This change will help facilitate the earlier diagnosis of endometriosis and promote more widespread use of medical therapy as opposed to surgery for many women. Accompanying this change will be a more patient-centric approach to care, as well as increased efforts to diminish the impact of healthcare disparities experienced by many women during their endometriosis journey. Join our faculty, Drs. Ayman Al-Hendy, Linda Bradley, Sawsan As-Sanie, Melissa Simon, James Simon, and Lee Shulman, as they address these many issues, with a focus on improving short- and long-term patient outcomes for women with endometriosis.

A paradigm change is occurring in the diagnosis and management of endometriosis. This change will help facilitate the earlier diagnosis of endometriosis and promote more widespread use of medical therapy as opposed to surgery for many women. Accompanying this change will be a more patient-centric approach to care, as well as increased efforts to diminish the impact of healthcare disparities experienced by many women during their endometriosis journey. Join our faculty, Drs. Ayman Al-Hendy, Linda Bradley, Sawsan As-Sanie, Melissa Simon, James Simon, and Lee Shulman, as they address these many issues, with a focus on improving short- and long-term patient outcomes for women with endometriosis.

A paradigm change is occurring in the diagnosis and management of endometriosis. This change will help facilitate the earlier diagnosis of endometriosis and promote more widespread use of medical therapy as opposed to surgery for many women. Accompanying this change will be a more patient-centric approach to care, as well as increased efforts to diminish the impact of healthcare disparities experienced by many women during their endometriosis journey. Join our faculty, Drs. Ayman Al-Hendy, Linda Bradley, Sawsan As-Sanie, Melissa Simon, James Simon, and Lee Shulman, as they address these many issues, with a focus on improving short- and long-term patient outcomes for women with endometriosis.

A paradigm change is occurring in the diagnosis and management of endometriosis. This change will help facilitate the earlier diagnosis of endometriosis and promote more widespread use of medical therapy as opposed to surgery for many women. Accompanying this change will be a more patient-centric approach to care, as well as increased efforts to diminish the impact of healthcare disparities experienced by many women during their endometriosis journey. Join our faculty, Drs. Ayman Al-Hendy, Linda Bradley, Sawsan As-Sanie, Melissa Simon, James Simon, and Lee Shulman, as they address these many issues, with a focus on improving short- and long-term patient outcomes for women with endometriosis.

A paradigm change is occurring in the diagnosis and management of endometriosis. This change will help facilitate the earlier diagnosis of endometriosis and promote more widespread use of medical therapy as opposed to surgery for many women. Accompanying this change will be a more patient-centric approach to care, as well as increased efforts to diminish the impact of healthcare disparities experienced by many women during their endometriosis journey. Join our faculty, Drs. Ayman Al-Hendy, Linda Bradley, Sawsan As-Sanie, Melissa Simon, James Simon, and Lee Shulman, as they address these many issues, with a focus on improving short- and long-term patient outcomes for women with endometriosis.

There are many unmet needs associated with the use of anti-inflammatory glucocorticoids when treating Duchenne muscular dystrophy, or DMD. These include multiple, often debilitating comorbidities that occur with long-term exposure. Join Drs. Hamid, Kuntz, and Monduy as they discuss key clinical trial data for a novel corticosteroid that may be a safer and possibly more effective option for patients with DMD than our current standard of care.

This activity is no longer available for continuing education credit.

Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

This activity is no longer available for continuing education credit.

Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

This activity is no longer available for continuing education credit.

Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

This activity is no longer available for continuing education credit.

Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

This activity is no longer available for continuing education credit.

Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

This activity is no longer available for continuing education credit.

Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

This activity is no longer available for continuing education credit.

Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

This activity is no longer available for continuing education credit.

Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

This activity is no longer available for continuing education credit.

Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

This activity is no longer available for continuing education credit.

Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

This program is no longer available for credit.

Despite the use of guideline-directed medical therapy, many patients with heart failure continue to have worsening symptoms. Enter baroreflex activation therapy, or BAT, an implantable FDA-approved cardiac autonomic modulation device. Listen in as Drs. Nirav Raval and Gurusher Panjrath explore data on its positive effects on exercise capacity, functional status, and quality of life. Do you know which of your patients may benefit from BAT?

This program is no longer available for credit.

Renowned international expert Dr. Roberto Romero joins Dr. Lee Shulman to walk us through maternal anti-fetal rejection. Find out about its pathophysiology, mechanisms of disease, approach to diagnosis, and potential treatment so that you can broaden your understanding and improve the care you provide.

The American College of Cardiology's 72nd Scientific Session & Expo featured the latest advancements in all fields of cardiovascular medicine, including cardio-oncology. To learn more, Dr. Javed Butler sits down with Dr. Ana Barac from the MedStar Washington Hospital Center to take a look at clinical data from the STOP-CA trial.

This program is no longer availble for credit

This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.

This program is no longer availble for credit

This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.

This Expert Exchange webcast is designed to help improve clinicians’ ability to utilize prognostic tools to monitor disease progression and implement appropriate treatment strategies in patients with ADPKD.

This activity is not available for continuing education credit.

This program is no longer available for credit.

Program Chairman:
Roberto Romero, MD, DMedSci
Chief, Perinatology Research Branch
Division of Maternal-Fetal Medicine and Obstetrics
Division of Intramural Research
NICHD/NIH/DHHS
Editor-in-Chief for Obstetrics
The American Journal of Obstetrics and Gynecology

As the platelet equivalent of hemolytic disease of the fetus and newborn, fetal and neonatal alloimmune thrombocytopenia (FNAIT) is an uncommon yet complex and life-threatening bleeding disorder that results from incompatibility between mother and baby for platelet-specific antigens. Despite relatively normal platelet function, in the setting of severe thrombocytopenia, intracranial hemorrhage is a consequence. Drs. Shulman and Bussel discuss advances in management strategies and concrete steps you can take to lower the risk and stop the progression of this disorder in your patients.

This program is no longer available for credit.

Program Chairman:
Roberto Romero, MD, DMedSci
Chief, Perinatology Research Branch
Division of Maternal-Fetal Medicine and Obstetrics
Division of Intramural Research
NICHD/NIH/DHHS
Editor-in-Chief for Obstetrics
The American Journal of Obstetrics and Gynecology

How well do you understand the biology of hemolytic disease of the fetus and newborn (HDFN)? What about its connection to the FcRn receptor pathway and IgG? Drs. Lee Shulman and Ken Moise go beyond the basics taught in medical school immunology and look more closely at FcRn’s role in protecting IgG. With an improved understanding of these mechanisms, we can expand therapeutic targets beyond the fetus and newborn and finally put the needles away.

This Expert Exchange webcast is designed to help improve clinicians’ understanding of the role radiologic imaging plays in the diagnosis and management of ADPKD.

This activity is not available for continuing education credit.

This program is no longer available for credit.

Program Chairman:
Roberto Romero M.D. D.Med Sci.
Chief, Perinatology Research Branch
Division of Maternal-Fetal Medicine and Obstetrics
Division of Intramural Research
NICHD/NIH/DHHS
Editor-in-Chief for Obstetrics
The American Journal of Obstetrics and Gynecology

Are you taking the right steps to consistently ensure all of your patients at risk of alloimmune disorders of pregnancy, specifically HDFN, receive a helping hand plus timely and appropriate clinical care? Despite having considerable clinical consequences, this area of medicine is not fully understood by many clinicians. Drs. Shulman and Moise provide expert insight on red blood cell alloimmunization, highlighting essential pathophysiology and current and evolving management strategies. Join us to learn new ways to approach this complicated and rare clinical condition.

This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.

This activity is not available for continuing education credit.

HER2-Directed ADCs in Breast Cancer

Please note: This activity is no longer available for continuing education credit.

There is a lack of available therapeutic options for the management of patients with myeloid malignancies, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). Novel therapeutic approaches are being evaluated, particularly those that target the NEDD8-activating enzyme (NAE). Evaluating the rationale for NAE inhibition, assessing emerging safety and efficacy data on use of NAE inhibitors in myeloid malignancies, and developing strategies based on the evolving implications of this research will allow for greater understanding of their potential impact on management and health outcomes of patients with MDS, CMML, and AML.

This Expert Exchange webcast aims to improve clinicians’ awareness of emerging agents in the treatment of patients with ADPKD.

This Expert Exchange webcast aims to improve clinicians’ ability to manage patients diagnosed with ADPKD.

This Expert Exchange webcast aims to improve clinicians’ ability to properly monitor disease progression and make treatment decisions based on prognostic indicators.

This Expert Exchange webcast aims to improve clinicians’ ability to detect and diagnose ADPKD in at-risk patients.

This Expert Exchange webcast aims to better define the importance radiological imaging plays in the management of patients with autosomal dominant polycystic kidney disease (ADPKD).

Following the approval of the first COVID-19 vaccine, mass-vaccination has made approving a vaccine difficult. How are the Food and Drug Administration and the Centers for Disease Control deciding on which vaccinations to authorize? Dr. Mira Irons and Shannon Curtis of the American Medical Association join Dr. Charles Turck to discuss authorization processes and recommendations for COVID-19 vaccines.

Please note: This activity is no longer available for continuing education credit.

This Expert Exchange activity is designed to make clinicians aware of the potential for emerging pharmacotherapies in treating patients with Parkinson’s disease.

You can access the Clinical Compendium for Novel Therapies to Manage OFF Episodes in Patients with Parkinson’s Disease by clicking the link here.

With the widespread impacts of the COVID-19 pandemic, the Centers for Medicare and Medicaid Services is now offering flexibility for clinicians participating in the Merit-Based Incentive Payment System, MIPS. But what exactly does that flexibility entail? Dr. Jennifer Caudle is joined by Koryn Rubin to discuss how this impacts healthcare professionals.

Since the original date of this recording, CMS has extended the deadline for its applications related to MIPS hardships from December 31, 2020 to February 1, 2021.

Despite evidence and guideline recommendations, renin-angiotensin-aldosterone system inhibitor (RAASi) therapy tends to be used suboptimally among patients with heart failure (HF), particularly in patients with chronic kidney disease (CKD). What are the real-world factors that influence RAASi treatment decisions in patients with HF who have or are at risk for hyperkalemia? Hear about how the CARE HK in HF study is being designed to explore the real-world data surrounding this question and its associated impact on outcomes.

Please note: This activity is no longer available for continuing education credit.

It is estimated that only 20% to 30% of patients with Crohn’s disease (CD) have a non-progressive or indolent course. While most patients with CD present with non-penetrating or non-stricturing disease, 50% of patients develop intestinal complications within 20 years of diagnosis. In this interactive CME activity, Dr. Hudesman presents the case of a patient with CD, highlighting the importance of early recognition of disease complications and considerations for surgical management. This real-world patient case offers you an opportunity to test your clinical skills for the successful management of inflammatory bowel disease (IBD) and learn more from an IBD expert faculty.

Please note: This activity is no longer available for continuing education credit.

Tune in as a multidisciplinary panel discusses a clinician's question about the appropriateness of combining two biologics in a very young child with several atopic diseases.

Please note: This activity is no longer available for continuing education credit.

A multidisiplinary panel is presented with a highly allergic, extremely refractory patient with atopic dermatitis. Her dermatologist wants to take the next step and start her on a biologic, but she's worried about the patient's occular history and dupilumab's conjunctivitis risk. Find out what the experts have to say about this doctor's dilemma.

Please note: This activity is no longer available for continuing education credit.

Infants have the highest incidence of atopic dermatitis in the US but the fewest treatment options. This is a case a doctor submitted about a baby who is refractory to multiple oral and topical treatments. A multidisciplinary panel discusses how they would approach the baby's treatment, emerging options for this vulnerable patient population, and if anything can be done now to prevent progression of the atopic march later.

Please note: This activity is no longer available for continuing education credit.

Nontuberculous mycobacteria lung disease (NTM-LD) is a relatively uncommon condition, although its prevalence is rising. In this interactive CME activity, Drs. Anne O’Donnell and Patrick Flume review two patient cases to demonstrate how clinicians can maintain a greater index of suspicion for the diagnosis of NTM-LD to enable timely and effective therapy. The management of NTM-LD remains challenging, owing to the need for long-term treatment, the potential for drug-related toxicities and patient nonadherence. These factors underscore the importance of specialty referral for the successful management of NTM-LD.

Please note: This activity is no longer available for continuing education credit.

The successful management of nontuberculous mycobacteria lung disease (NTM-LD) remains challenging owing to the need for long-term treatment, the ongoing risks of adverse drug reactions, and the potential for nonadherence. These factors underscore the importance of specialty referral and shared decision making in the successful management of NTM-LD, as Dr. Anne O’Donnell and her patient Brinkley exemplify.

Please note: This activity is no longer available for continuing education credit.

Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with significant morbidity and negatively impacts quality of life. The good news is that biologic therapies targeting type 2 inflammatory pathways provide additional treatment options for CRSwNP. However, clinicians not only need to accurately diagnose nasal polyps in patients but also recognize the role of the underlying pathology to incorporate biologic agents into treatment regimens when appropriate, as Dr. Joseph K. Han explains.

Please note: This activity is no longer available for continuing education credit.